Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 2,675 shares of the business's stock in a transaction dated Thursday, June 26th. The stock was sold at an average price of $36.13, for a total value of $96,647.75. Following the transaction, the chief financial officer directly owned 21,004 shares of the company's stock, valued at $758,874.52. This represents a 11.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Yajing Chen also recently made the following trade(s):
- On Monday, June 2nd, Yajing Chen sold 9,618 shares of Zai Lab stock. The shares were sold at an average price of $30.00, for a total value of $288,540.00.
- On Friday, April 4th, Yajing Chen sold 924 shares of Zai Lab stock. The stock was sold at an average price of $33.11, for a total value of $30,593.64.
- On Wednesday, April 2nd, Yajing Chen sold 5,280 shares of Zai Lab stock. The shares were sold at an average price of $35.89, for a total value of $189,499.20.
Zai Lab Stock Up 0.7%
NASDAQ:ZLAB traded up $0.23 on Monday, reaching $34.97. The stock had a trading volume of 847,285 shares, compared to its average volume of 909,132. The company has a market capitalization of $3.88 billion, a P/E ratio of -14.04 and a beta of 0.96. The stock has a fifty day moving average price of $33.57 and a 200-day moving average price of $31.19. Zai Lab Limited Unsponsored ADR has a 1-year low of $16.01 and a 1-year high of $44.34.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.05. Zai Lab had a negative return on equity of 33.35% and a negative net margin of 60.26%. The business had revenue of $106.49 million for the quarter, compared to analyst estimates of $118.40 million. Sell-side analysts predict that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
ZLAB has been the topic of several analyst reports. Scotiabank initiated coverage on shares of Zai Lab in a report on Friday, March 7th. They issued a "sector outperform" rating and a $55.00 price target on the stock. Wall Street Zen lowered shares of Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday. Leerink Partners upped their target price on shares of Zai Lab from $73.00 to $75.00 and gave the company an "outperform" rating in a research note on Monday. Cantor Fitzgerald restated an "overweight" rating on shares of Zai Lab in a research note on Thursday, March 27th. Finally, JPMorgan Chase & Co. lifted their price objective on Zai Lab from $44.00 to $51.00 and gave the company an "overweight" rating in a report on Thursday, March 13th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Zai Lab currently has a consensus rating of "Moderate Buy" and an average target price of $54.28.
Check Out Our Latest Report on Zai Lab
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. FMR LLC increased its position in Zai Lab by 749.1% in the 4th quarter. FMR LLC now owns 5,475,505 shares of the company's stock valued at $143,403,000 after acquiring an additional 4,830,646 shares in the last quarter. RTW Investments LP bought a new stake in shares of Zai Lab during the fourth quarter valued at approximately $65,714,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Zai Lab by 46,222.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company's stock valued at $77,058,000 after purchasing an additional 2,127,598 shares in the last quarter. RA Capital Management L.P. bought a new position in Zai Lab in the 4th quarter worth approximately $33,917,000. Finally, Principal Financial Group Inc. lifted its holdings in Zai Lab by 63.6% during the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company's stock worth $104,257,000 after buying an additional 1,121,856 shares in the last quarter. 41.65% of the stock is owned by institutional investors.
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Read More
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
